Policy ambition outpaces pharmacy capacity, warns Brine
A sharp opinion piece published on 7 May 2026 is putting a spotlight on the gap between pharmacy policy ambition and the practical capacity needed to deliver it — and for pre-reg pharmacists, it is exactly the kind of system-level tension you need to understand before you qualify. The argument is straightforward: when the vision outpaces the infrastructure, it is patients and frontline practitioners who absorb the strain. That is not reform; it is risk transfer.
What's happened
Steve Brine, writing on 7 May 2026, has set out a pointed critique of how pharmacy policy is currently being implemented in the United Kingdom. The central concern is that the ambition driving reform — bringing more clinical expertise into the heart of general practice, expanding patient access, and making better use of the skills already in the system — is not being matched by the capacity required to deliver it safely and sustainably.
Pharmacists were identified as central to the original vision. The expectation was that clinical pharmacy, embedded in primary care, would shift how patients access expertise and how general practice manages demand. But Brine's assessment is that the execution has created a structural fault line. As he puts it: "We are, in effect, running two policies in parallel." That phrase captures the core problem — two different directions pulling on the same workforce at the same time, without the resource base to make either work properly.
The piece does not argue against the ambition itself. The direction of travel — more pharmacist involvement in clinical care, greater integration with GP teams, improved medicines optimisation — is not contested. What is contested is whether the system has been given what it needs to get there.
Why it matters for pre-reg pharmacists
You are entering the profession at exactly the moment this tension is most acute. The policy landscape you are qualifying into is one that promises expanded scope, genuine clinical roles, and a real seat at the table in primary care. That is genuinely exciting. But Brine's analysis asks a harder question: are the systems, the staffing, the supervision frameworks, and the infrastructure in place to support that ambition — or are newly qualified pharmacists being asked to step into roles that the wider system has not yet properly resourced?
This matters practically. If you are heading into a primary care network (PCN) role, a GP practice placement, or a community pharmacy with an expanding clinical remit, the gap between what policy promises and what is operationally supported can fall on you. Workload without adequate support is not an opportunity; it is a risk — to your wellbeing, to your professional development, and ultimately to patient safety.
Understanding this dynamic also makes you a sharper practitioner. Pharmacists who can read policy not just as aspiration but as implementation challenge are the ones who will be effective advocates for their teams, their patients, and themselves. The ability to identify when ambition has outrun capacity — and to raise that clearly and professionally — is a clinical and professional skill, not just a political opinion.
There is also a workforce dimension worth naming. Running two policies in parallel, as Brine describes it, places particular pressure on the existing pharmacist workforce. Pre-reg and early-career pharmacists are not immune to that pressure; in many settings, they are disproportionately exposed to it, precisely because they are newer, often less assertive about boundaries, and placed in environments that may not have robust supervision structures in place.
GPhC exam relevance
The GPhC registration assessment tests not just clinical knowledge but professional judgement — and professional judgement includes understanding the system you are working within. Several competency areas connect directly to the issues Brine raises.
The GPhC's standards for pharmacy professionals require registrants to work within their competence and to raise concerns when patient safety or the quality of care is at risk. If you are placed in a role where the gap between policy expectation and operational reality creates risk, recognising that — and knowing what to do about it — is an assessed professional behaviour, not an optional extra.
Medicines optimisation in primary care, which is a core area for PCN clinical pharmacists, requires understanding of prescribing systems, repeat prescribing processes, polypharmacy reviews, and interface challenges between secondary and primary care. These are all areas where capacity constraints play out in practice. A PCN pharmacist understaffed and overloaded cannot safely conduct structured medication reviews at the depth the policy intends. That is a patient safety issue, and it is the kind of contextual reasoning the registration assessment expects you to be capable of.
The MEP (Medicines, Ethics and Practice guide) framework around professional accountability is also relevant here. Being clear about the limits of your own practice, escalating appropriately, and not accepting unsafe working conditions silently — these are not just regulatory obligations in the abstract; they are daily realities in under-resourced environments.
For calculation and clinical reasoning questions in the assessment, the broader context is less directly relevant. But for the situational and professional judgement elements, understanding the system pressures that shape clinical decisions is exactly the kind of sophistication that distinguishes a strong candidate from one who can only answer in isolation.
Career angle
For pre-reg pharmacists currently on placement, the practical takeaway from Brine's analysis is to pay close attention to the structural realities of wherever you are working — not just the clinical protocols. Ask yourself: what does the workflow actually look like? Is the team resourced to deliver what it is being asked to deliver? Where are the pressure points? Who absorbs them?
In community pharmacy, the parallel policy problem may manifest as an expectation to deliver an expanding range of clinical services — Pharmacy First, hypertension case-finding, contraception services, and more — while managing an unchanged or reduced dispensing workforce. Understanding that tension, and how your supervising pharmacist navigates it, is a legitimate part of your training.
In primary care and PCN roles, the issue may look different: an expectation to be a full clinical partner in a GP team without the infrastructure of support — clinical supervision, clear escalation pathways, IT access — that would make that sustainable. Knowing how to have a professional conversation about what you need to practise safely is a skill you should be developing now, not after you qualify.
Early-career pharmacists who understand this landscape will also be better positioned when it comes to job selection. A role that sounds ambitious on paper but sits in a system with no capacity to support it properly is worth scrutinising carefully. Ask about supervision. Ask about workload. Ask about how the service is funded and staffed. These are not awkward questions; they are professional due diligence.
There is also a longer-term professional identity point here. The pharmacist workforce that Brine and others are discussing is not a passive object of policy — it is a profession with the capacity to shape how reform is implemented. Engaging with this debate, reading the analysis, forming your own views, and being able to articulate them is part of becoming a pharmacist who contributes to the profession rather than simply working within it.
What's next
Watch how the primary care pharmacy workforce story develops over the coming months. The question of whether capacity is being built to match policy ambition is not going to resolve itself quickly. Workforce planning, funding settlements, and the detail of how clinical pharmacist roles are structured and supervised will all matter.
For your own preparation, treat this kind of policy analysis as part of your broader professional development — not separate from your GPhC exam revision but connected to it. The registration assessment is testing whether you are ready to practise safely and effectively in the real NHS. The real NHS is exactly the contested, under-resourced, ambition-rich environment that Brine is describing.
If you are on placement now, seek out conversations with your supervising pharmacist about how they experience the gap between policy expectation and daily reality. Those conversations will give you richer insight into professional practice than any case study. And if you are approaching the assessment, make sure you can reason clearly about scenarios that involve systemic pressure — because those are the scenarios that test genuine professional judgement, not just recalled knowledge.
Source: Chemist+Druggist — https://www.chemistanddruggist.co.uk/analysis/opinion/political-pills-ambition-without-capacity-is-risk-not-reform-LLN76HZJLBBCZM7HSBODO4UT3Y/